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Background: Experience in treating human coronavirus (HCoV) infections might help to
identify effective compounds against novel coronaviruses. We therefore performed a
secondary subgroup-analysis of data from an open-label, uncontrolled clinical trial
published in 2015 investigating the proanthocyanidin-rich Pelargonium sidoides extract
EPs 7630 in patients with the common cold.
Methods: 120 patients with common cold and at least 2 out of 10 common cold
symptoms received one film-coated 20 mg tablet EPs 7630 thrice daily for 10 days in
an uncontrolled, interventional multicentre trial (ISRCTN65790556). At baseline, viral
nucleic acids were detected by polymerase chain reaction. Common cold-associated
symptoms and treatment satisfaction were evaluated after 5 days and at treatment end.
Based on the data of patients with proof of viral nucleic acids, we compared the course of
the disease in patients with or without HCoV infection.
Results: In 61 patients, viral nucleic acids were detected. Of these, 23 (37.7%) were
tested positive for at least one HCoV (HCoV subset) and 38 (62.3%) for other viruses only
(non-HCoV subset). Patients of both subsets showed a significant improvement of
common cold symptoms already after 5 days of treatment, although the observed
change tended to be more pronounced in the HCoV subset. At treatment end, more
than 80% of patients of both groups were completely recovered or majorly improved. In
both subsets, less than 22% of patients took concomitant paracetamol for antipyresis. The
mean number of patients’ days off work or school/college was similar (0.9 ± 2.6 days in
HCoV subset vs 1.3 ± 2.8 days in non-HCoV subset). In both groups, most patients were
satisfied or very satisfied with EPs 7630 treatment.
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Conclusion: EPs 7630 treatment outcomes of common cold patients with confirmed
HCoV infection were as favourable as in patients with other viral infections. As this trial was
conducted before the pandemic, there is currently no evidence from clinical trials for the
efficacy of EPs 7630 in patients with SARS-CoV-2 infection. Dedicated non-clinical studies
and clinical trials are required to elucidate the potential of EPs 7630 in the early treatment of
HCoV infections.
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INTRODUCTION
The current COVID-19 pandemic has boosted interest in
treatment options for human coronavirus (HCoV) infections.
Currently, seven HCoVs have been reported (Liu et al., 2020).
The novel betacoronaviruses (β-CoVs) MiddleEast respiratory
syndrome coronavirus (MERS-CoV), severe acute respiratory
syndrome coronavirus (SARS-CoV) and SARS-CoV-2 cause
the most severe respiratory syndromes. However, severe and
life-threatening complications like pneumonia have also been
reported for other HCoVs (Schildgen, 2018; Pillaiyar et al., 2020).
Due to the route of infection via the respiratory epithelium, there
are similarities in the clinical picture between SARS-CoV-2 and
other HCoVs (Rothan & Byrareddy, 2020). At disease onset,
cough, sputum production, and sore throat are frequently
present. Fever, fatigue, and headache are reported at later
phases. Experience from treating infections with common-cold
associated HCoVs [i.e., HCoV-HKU1, HCoV-OC43, HCoV-
NL63, HCoV-229E (Liu et al., 2020)] might therefore support
the identification of compounds with therapeutic potential
against novel severe coronavirus infections.
Herbal medicinal products together with NSAIDs, vitamins,
and trace elements are commonly used in the treatment of acute
upper respiratory tract infections, which are mostly caused by
viruses. Among others, active substances include tannins, e.g.,
proanthocyanidins, which are known to interact with viral
proteins and are able to change or inhibit their structure and
functionality (Hensel et al., 2020). Particularly,
proanthocyanidins exert antiviral effects such as inhibition of
viral proteins involved in cell adhesion or virus release (Derksen
et al., 2014; Quosdorf et al., 2017; Tsukuda et al., 2017), inhibition
of virus-induced autophagy (Dai et al., 2012), and inhibition of
host cell signalling (Lee et al., 2017).
The proanthocyanidin-rich extract EPs 7630 (EPs® 7630 is a
proprietary extract and active ingredient in pharmaceuticals
manufactured by Dr Willmar Schwabe GmbH and Co. KG.)
from the roots of Pelargonium sidoides possesses promising
immune-modulating as well as antiviral properties (Antonelli
et al., 2020; Brendler et al., 2020; Mani et al., 2020; Silveira et al.,
2020). Pelargonium sidoides is a plant native to South Africa,
which shares the same genus (Pelargonium) with the common
ornamental geraniums and which roots have been used as herbal
remedies for respiratory and gastrointestinal infections centuries-
long by the local South African populations (Careddu &
Pettenazzo, 2018). The plant became known in Europe
120 years ago, when it was described by the Englishman
Charles Henry Stevens and its root praised as a new remedy
for tuberculosis (Bladt & Wagner, 2007). Today, EPs 7630 is the
active ingredient of medicinal products in both tablet and liquid
forms and used in children from the age of one year, adolescents
and adults for the treatment of respiratory tract infections in
several countries in Europe, Asia, Australia, as well as Central and
South America. In adults, the recommended daily dose is 30
drops of liquid solution or one 20 mg tablet thrice daily.
A number of non-clinical studies demonstrated activity of EPs
7630 against a variety of respiratory viruses such as HCoV (HCo-
229E), influenza A virus (H1N1, H3N2), respiratory syncytial
virus (RSV), and parainfluenza virus (Michaelis et al., 2011;
Theisen & Muller, 2012). In cell culture experiments, EPs 7630
inhibited the attachment of HIV-1 to human immune cells and
viral entry (Helfer et al., 2014). Moreover, EPs 7630 inhibited
influenza A virus replication by inhibition of hemagglutinin and
neuraminidase activity (Theisen & Muller, 2012), which was at
least in part mediated by the proanthocyanidin constituents. In
human bronchial epithelial cells, EPs 7630 reduced rhinovirus-16
replication by downregulating the expression of inducible co-
stimulator (ICOS) and its ligand (ICOSL) as well as the surface
calreticulin receptor, whereas levels of host defence supporting
proteins were increased (Roth et al., 2019). Mechanistically, EPs
7630 significantly reduced host cell attachment of various viruses
and prevented virus release from infected cells. Moreover, EPs
7630 stimulated the release of nitric oxide (NO), type I interferon
(IFN), and different cytokines involved in host defense
mechanisms (Kolodziej, 2011; Witte et al., 2015; Witte et al.,
2020). In athletes, EPs 7630 modulated the immune response
during strenuous exercise by increasing immunoglobulin α
production in saliva, decreasing interleukin (IL)-15 and IL-6
levels in the serum, and reducing IL-15 in the nasal mucosa
(Luna et al., 2011). EPs 7630 was also found to prevent asthma
attacks provoked by rhinovirus in children, probably by
interfering with IL-6-, IL-8-, and IL-16-mediated inflammation
(Tahan & Yaman, 2013).
Over the last 25 years, more than 30 clinical trials have
investigated EPs 7630 for the treatment of acute respiratory
tract infections (ARTI) (Brendler et al., 2020). Systematic
reviews and meta-analyses have provided evidence that EPs
7630 is effective and well-tolerated in adults, children and
adolescents with ARTI such as acute bronchitis or the
common cold (Agbabiaka et al., 2008; Timmer et al., 2013;
Matthys et al., 2016; Kamin et al., 2018; Schapowal et al.,
2019; Seifert et al., 2019; Wopker et al., 2020; Seifert et al.,
2021). Most randomized controlled trials investigating EPs
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7630 were performed in patients with acute bronchitis. A
systematic meta-analysis of placebo-controlled clinical trials
showed the efficacy of treatment with EPs 7630 in this
indication, with a significantly faster and more effective
reduction of bronchitis-specific symptoms (Agbabiaka et al.,
2008). For the indication common cold, a first double-blind,
randomized controlled trial in 103 adults was reported in 2007, in
which patients were treated with EPs 7630 (3 × 30 drops/d) or
placebo for up to 10 days (Lizogub et al., 2007). Until day 5, the
primary outcome measure “Sum of the Symptom Intensity
Differences” (SSID) had significantly improved by 14.6 ± 5.3
points (mean ± SD) in the EPs 7630 group compared to 7.6 ± 7.5
points in the placebo group of this trial. The mean duration of
inability to work was also significantly lower in the EPs 7630
group compared to placebo. In a second part of this trial, which
was published separately (Riley et al., 2018), 104 patients with
common cold were randomized to a ten-days treatment with 3 ×
60 drops/d EPs 7630 or placebo. Again, the mean SSID from
baseline to day 5 was statistically significantly higher for EPs 7630
compared to placebo (16.0 ± 7.4 vs. 8.3 ± 7.6 points). After 10
days, 90.4% of EPs 7630 patients and 21.2% of placebo patients
were clinically cured. In another trial reported in 2019 (Riley
et al., 2019), 105 adults suffering from common cold symptoms
were randomized to a treatment with one film-coated tablet
containing 40 mg EPs 7630 or matched placebo thrice-daily
for 10 consecutive days. In this trial, the SSID had
significantly improved by 12.5 ± 4.4 points the EPs 7630
group compared to 8.8 ± 6.8 points in the placebo group at
day 5. Moreover, on day 10, EQ-VAS status, activity level, and the
general well-being were significantly better in the EPs 7630 group
than in the placebo group.
The favourable safety profile of EPs 7630 has been confirmed
in clinical trials with a total of more than 10,000 patients
including adults, adolescents and children as well as from
decades of market experience (Matthys et al., 2013; Careddu &
Pettenazzo, 2018; Brendler et al., 2020).
Recently, we reported on an open-label, interventional,
uncontrolled, phase IV clinical trial designed to obtain
further information on the tolerability and effectiveness of
EPs 7630 in a real-world setting in patients suffering from the
common cold (Keck et al., 2015). This clinical trial showed the
excellent tolerability of EPs 7630 in a 10 days’ treatment of
adult patients suffering from the common cold. Moreover,
most patients showed a favourable course of recovery from the
disease. In a secondary subgroup-analysis of trial data (Keck
et al., 2018), the association between the detection of viral
nucleic acids at the start of treatment and the subsequent
course of the disease specific symptoms was further
investigated. This analysis revealed that the most frequently
detected viruses by molecular testing at baseline were
enterovirus/rhinovirus followed by HCoV-HKU1 and
HCoV-OC43 (Keck et al., 2018).
We performed a secondary subgroup-analysis of this clinical
trial and compared treatment outcomes in patients with or
without HCoV to investigate whether the proanthocyanidin-
rich extract EPs 7630 could be helpful in the treatment of
HCoV-associated ARTI.
MATERIALS AND METHODS
This was a secondary subgroup-analysis of a 10 days open-label,
uncontrolled, interventional multicentre phase IV clinical trial
conducted in the out-patient clinics of eight hospitals in Austria.
The trial was registered at the ISRCTN registry
(ISRCTN65790556) and its protocol was approved by the
responsible ethics committee. The principles of Good Clinical
Practice and the Declaration of Helsinki were adhered to. All
patients provided written informed consent.
Details on the methodology and the main results for the total
population of the underlying clinical trial are described elsewhere
(Keck et al., 2015; Keck et al., 2018). In the following, only the
methodological details and results for the subset analysis
are given.
Participants
Eligible participants were male or female outpatients aged
18 years or older, with a clinical diagnosis of common cold












Exclusion criteria were: any acute respiratory tract disease
other than the common cold, obstructive anatomic
nasopharyngeal lesions (e.g., nasal polyps), severe septal
deviations, previous or planned surgery of the nose or
paranasal sinuses, chronic pulmonary diseases, allergic rhinitis,
conditions known to cause sore throat such as
tonsillopharyngitis, drugs, aphthous ulcers, or candida.
Interventions
Patients took one film-coated tablet EPs 7630 (Kaloba®,
Austroplant Arzneimittel, Vienna, Austria) thrice daily for 10
days. Each tablet contained 20 mg herbal drug preparation from
the roots of Pelargonium sidoides (1:8–10), dried; extraction
solvent: ethanol 11% (w/w). Roots of Pelargonium sidoides
were collected in South Africa (e.g., Eastern Cape). The dried
material was tested in an array of biochemical and phytochemical
methods in order to confirm the quality and identity of the herbal
material. Pharmacognosy was done by the quality control
department of Dr. Willmar Schwabe GmbH and Co. KG. A
voucher specimen of every lot is deposited in the Department of
Pharmacognosy to be retained for ten years. In addition, the
herbal material is tested with respect to purity (e.g., heavy metals,
and microbiological quality). EPs 7630 is classified by the
European Pharmacopoeia as “other extract” and therefore not
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adjusted to a specific content of constituents. Independent of this
formal classification, the constituents of this herbal active
ingredient are described in detail by Schoetz and colleagues
(Schoetz et al., 2008). Approximately 80% m/m of the extract
are assigned to six major groups of constituents, with oligomeric
prodelphinidines (commonly designated in this context as
polyphenols) being the most significant group (approximately
40% of the dried extract). The film-coated tablets used in the
underlying clinical trial were tested and released compliant with
drug GMP and the European Pharmacopoeia according to
written, authorized and validated analytical procedures with
respect to identity, extract content, uniformity, disintegration,
and microbiological purity.
Treatment compliance was assessed by counting the number
of the remaining film-coated tablets at trial end.
Concomitant common cold medication which might impair
the interpretation of trial results was not allowed except for up to
500 mg paracetamol every 6 h in the case of fever over 38.5°C.
Outcomes
At each visit (baseline, day 5, and day 10), the investigator
assessed the 10 CCS (see above) on a 4-point rating scale (0 
not present to 3  severe). Ratings were then summed up to a total
CCS score.
Furthermore, the 8 additional common cold-relevant
complaints (CRC)
• pulmonary rales at auscultation
• sputum production
• chest pain while coughing
• chills
• exhaustion
• loss of appetite
• diarrhoea
• muscle aches
were assessed by the investigator on a 4-point rating scale (0 
not present to 3  severe). These 8 individual ratings were
summed up to a total CRC score.
An overall symptom score was calculated from the total CCS
and CRC scores.
Participants were instructed to record the intensity of
15 disease-related symptoms (runny nose, congested nose,
sneezing, sore throat, scratchy throat, hoarseness, coughing,
headache, malaise, chills, chest pain during coughing, loss of
appetite, restless sleep, limitation of usual daily activities, and
muscle ache) by means of a 5-point rating scale (0  not at all to
4  severe) in the diary and a total score was calculated.
Moreover, we laid a focus on symptoms of the CCS or CRC
described as similar between SARS-CoV-2, earlier β-CoVs as well
as other common acute upper respiratory tract infections (fever,
cough, malaise, sputum production, headache, and sore throat)
and analysed each of these symptoms separately.
Recovery from the common cold was rated by both the
investigator and the patient using the Integrative Medicine
Outcomes scale (IMOS) (Steinsbekk et al., 1999). The patient’s
satisfaction with treatment was assessed using the Integrative
Medicine Patient Satisfaction Scale (IMPSS) (Steinsbekk et al.,
1999). Additionally, the number of days off work or school and
the use of paracetamol were documented. Further methodological
details on the outcomes of this clinical trial are described
elsewhere (Keck et al., 2015; Keck et al., 2018).
Molecular Diagnostic Assays
At baseline, molecular testing for viruses was performed by taking
a nasopharyngeal swab from both nostrils with a sterile brush.
Total nucleic acid (NA), i.e., deoxyribonucleic acid (DNA) and
ribonucleic acid (RNA), was isolated from the samples by means
of the QIAamp nucleic acid isolation kit (Qiagen, Hilden,
Germany). The amount of isolated nucleic acid was measured
by absorbance. For viral testing, an aliquot was applied to the
xTAG® Respiratory Viral Panel (RVP) FAST assay (Abbott,
Vienna, Austria) and performed according to the instructions
of the manufacturer. Complementary DNA (cDNA) were
generated from RNA by reverse transcription (RT) and
amplified by polymerase chain reaction (PCR) afterwards
within the single step RT-PCR reaction. After RT-PCR, the
amplicons were hybridized onto virus species-specific DNA
probes immobilized on Luminex beads. Virus species were
identified using Luminex technology, with signal
measurements of virus-specific hybridization signals specified
for the xTAG® RVP FAST assay conducted on a Luminex®
200™ System (Luminex, Austin, TX, United States).
Statistics
The analysis plan of the original analysis was applied to two
additional subgroups of patients. Prior to the analysis, patients
with and without positive HCoV NA were identified. Descriptive
post-hoc comparisons were performed in NA-positive patients
with and without proof of HCoV (HCoV/non-HCoV subset) at
baseline. Patients in whom HCoV as well as non-HCoV species
had been detected were assigned to the HCoV subset. Within
each subset, descriptive summary statistics and 95% confidence
intervals (CIs) were computed, and p-values were determined for
change over time. At least one post-baseline assessment of the
analysed outcome was required for eligibility of the analyses of
the course of the common cold as documented by the
investigators (full analysis set, FAS). In this case, missing data
were replaced by carrying the last valid observation forward. No
replacement strategy was applied in cases of the analysis of data
derived from the patient diaries. Two-sided p-values of up to 0.05
were considered to be descriptively significant for statistical tests
(Fisher’s exact test and Mann-Whitney-U-test for qualitative and
quantitative between-group comparisons, respectively; Wilcoxon
signed rank test for within-group comparisons). Data are given as
mean ± SD if not stated otherwise.
RESULTS
Patients
Between January 2011 and November 2012, 120 patients were
enrolled and underwent treatment. Swab samples were available
from 119 patients and virus NA were detected in 61 patients (51.3%).
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Of the 61 patients, 23 (37.7%) were HCoV-positive and 38
(62.3%) HCoV-negative (Table 1).
In the HCoV subset, 11/23 (47.8%) patients tested positive for
HCoV-HKU1, 7/23 (30.4%) for HCoV-OC43, 2/23 (8.7%) for
HCoV-NL63, and 4/23 (17.4%) for HCoV-229E. Of these, 7/23
(30.4%) patients of the HCoV subset tested positive for more than
one virus: 1 patient for both HCoV-HKU1 and influenza B virus;
1 patient for both HCoV-HKU1 and respiratory syncytial virus
(RSV) A; 2 patients for both HCoV-HKU1 and enterovirus/
rhinovirus; 1 patient for both HCoV-229E and enterovirus/
rhinovirus; 1 patient for HCoV-HKU1, HCoV-OC43, and
RSV A; and 1 patient for HCoV-HKU1, enterovirus/
rhinovirus, and parainfluenza virus 2.
In the non-HCoV subset, 25/38 (65.8%) patients tested
positive for enterovirus/rhinovirus, 4/38 (10.5%) for
parainfluenza virus 2, 4/38 (10.5%) for influenza A virus, 2/38
(5.3%) for RSV A, 3/38 (7.9%) for human metapneumovirus
(HMPV), 2/38 (5.3%) for RSV B, 1/38 (2.6%) for parainfluenza
virus 1, and 1/38 (2.6%) for parainfluenza virus 3. Of these, 4/38
(10.5%) patients tested positive for more than one virus: 1 patient
for both enterovirus/rhinovirus and parainfluenza virus 1; 2
patients for both enterovirus/rhinovirus and parainfluenza
virus 2; 1 patient for both parainfluenza virus 2 and RSV A.
One patient of the non-HCoV subset withdrew consent prior
to the first post-baseline assessment without giving the reason.
Therefore, 23 and 37 patients could be analysed for the HCoV
and non-HCoV subset, respectively.
There were no statistically significant differences in baseline
characteristics between the HCoV and non-HCoV subset
concerning gender, age, height, weight, or duration of
common cold symptoms prior to trial inclusion (Table 1). All
patients but one were Caucasians. Slightly more patients in the
HCoV subset were smokers or former smokers compared to the
non-HCoV subset (60.9 vs 52.6%).
Common Cold Symptoms and Further
Common Cold-Relevant Complaints
At baseline, patients of the HCoV and non-HCoV subsets showed a
similar CCS total score as rated by the investigators (Table 2). After
5 days of treatment with EPs 7630, a somewhat greater improvement
in theCCS could be seen in the patients of theHCoV subset compared
to non-HCoV patients, but this was no longer the case at the end of
the treatment (day 10). At both time points, there were no statistically
significant differences between both subsets. Comparable results were
observed regarding the time course of the CRC and the overall
symptom score (Figure 1; Table 2). Patients of both subsets
achieved descriptively significant mean score reductions of ≥50%
of baseline values already after 5 days of EPs 7630 treatment and
continued to improve until day 10. There were no statistically
significant differences between both subsets.
Figure 2 depicts the severity of the symptoms fever, cough,
malaise, sputum production, headache, and sore throat as rated by
the investigator during the trial. Fever was present in only 1 patient of
each subset at the start of treatment. In both cases, symptom severity
was assessed as moderate. No considerable change was observed
during the trial. With respect to the severity of the symptoms cough,
malaise, sputum production, headache, and sore throat, patients of
both subsets showed comparable improvements; there was a
somewhat faster response to the treatment in the HCoV subset.
However, these group differences were not statistically significant.
The mean total scores of the patients’ self-rating documented
in the diaries also showed a continuous improvement in both
subsets until treatment end (Figure 3). Again, there was a
somewhat faster decrease for the HCoV group until day 5.
Nevertheless, no statistically significant differences were seen.
Recovery From the Disease and
Satisfaction With Treatment
According to the investigators’ IMOS ratings, 68.2% of HCoV
patients and 43.2% of non-HCoV patients showed at least major
improvements after 5 days of treatment with EPs 7630 (p < 0.001,
Fisher’s Exact Test). At treatment end, 87.0% of HCoV patients
were completely recovered or majorly improved compared to
81.1% of non-HCoV patients (Figure 4).
Moreover, IMPSS indicated a somewhat higher treatment
satisfaction in the HCoV cohort, but there were no statistically
significant differences between both subsets. A total of 18/23
patients (78.3%) of the HCoV subset were satisfied or very
satisfied with treatment. In the non-HCoV subset, 22/38 (57.9%)
patients rated satisfaction with treatment accordingly (Figure 4). No
TABLE 1 | Baseline characteristics (number (%) of patients or mean ± SD, by HCoV detection).
Virus NA HCoV (n = 23) Non-HCoV (n = 38)
Female 17 (73.9%) 27 (71.1%)
Male 6 (26.1%) 11 (28.9%)
Age (years) 34.2 ± 11.7 37.6 ±12.8
Height (cm) 171.3 ± 9.6 172.2 ± 8.2
Weight (kg) 70.4 ± 11.0 72.5 ± 14.7
Duration of common cold symptoms (hours) 50.1 ± 16.3 50.1 ± 16.8
Never smoker 9 (39.1%) 18 (47.4%)
Former smoker 4 (17.4%) 6 (15.8%)
Current smoker 10 (43.5%) 14 (36.8%)
Number of virus species detected
1 16 (69.6%) 34 (89.5%)
2 5 (21.7%) 4 (10.5%)
3 2 (8.7%) 0 (0.0%)
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patient of the HCoV subset was dissatisfied or very dissatisfied with
the treatment compared to 1 patient in the non-HCoV subset.
Use of Paracetamol
During the trial, paracetamol was taken by a total of 11/61
(18.0%) patients with proof of viral NA. In the HCoV and
non-HCoV subset, paracetamol use was reported for 3/23
(13.0%) and 8/38 (21.1%) patients, respectively.
Inability to Work
With 0.9 ± 2.6 and 1.3 ± 2.8 days, respectively, the mean number
of days off work or school/college was comparable for patients in
the HCoV subset compared to the non-HCoV subset.
Tolerability and Safety
A total of 10 adverse events (AEs) were observed in 7 of the 61
patients (11.5%) analysed: 5 AEs were reported by 4 patients
(10.5%) in the non-HCoV subset and 5 AEs by 3 patients
(13.0%) in the HCoV subset. For the reported 5 AEs in the
non-HCoV subset, a causal relationship with the study
medication was assessed as unlikely. In the HCoV subset, a
causal relationship with the study medication was assessed as
unlikely for 2 AEs of 2 patients and as unrelated for 3 AEs in 1
patient. In both subsets, the MedDRA System Organ Class
with the largest number of patients affected by an AE was
gastrointestinal disorders (non-HCoV: 3 (7.9%) patients;
HCoV: 2 (8.7%) patients).
TABLE 2 | Common cold associated symptoms–baseline total score and change between baseline and subsequent visits (CCS, common cold symptoms; CRC, further
common cold relevant complaints; CCS + CRC, overall symptom score; investigator ratings, mean ± SD and Wilcoxon test for change vs. baseline; FAS; *two-sided
p-value of Wilcoxon signed rank test).
Virus NA HCoV Non-HCoV
n Mean ± SD p* n Mean ± SD p*
CCS Baseline 23 11.8 ± 3.0 38 11.4 ± 3.6
Change, day 5 22 −7.0 ± 5.6 <0.01 37 −5.7 ± 3.5 <0.01
Change, day 10 23 −9.5 ± 4.3 <0.01 37 −9.4 ± 3.5 <0.01
CRC Baseline 23 3.1 ± 2.8 38 3.4 ± 2.1
Change, day 5 22 −2.0 ± 2.3 <0.01 37 −2.0 ± 1.9 <0.01
Change, day 10 23 −2.3 ± 2.6 <0.01 37 −2.7 ± 1.6 <0.01
CCS + CRC Baseline 23 14.9 ± 4.7 38 14.8 ± 5.1
Change, day 5 22 −9.0 ± 6.7 <0.01 37 −7.7 ± 4.4 <0.01
Change, day 10 23 −11.9 ± 5.9 <0.01 37 −12.1 ± 4.4 <0.01
FIGURE 1 | Course of the common cold symptoms (CCS), further common cold relevant complaints (CRC) and overall symptom score (CCS + CRC) in the HCoV
and non-HCoV subsets during the trial. CCS, HCoV: CCS investigator rating of patients tested positive for at least one HCoV; CCS, non-HCoV: CCS investigator rating of
patients tested positive for viruses other than HCoV; CRC, HCoV: CRC investigator rating of patients tested positive for at least one HCoV; CRC, non-HCoV: CRC
investigator rating of patients tested positive for viruses other than HCoV; CCS +CRC, HCoV: CCS +CRC total score subset patients tested positive for at least one
HCoV; CCS + CRC, non-HCoV: CCS + CRC total score subset patients tested positive for viruses other than HCoV.
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FIGURE 2 | Symptom severity of (A) cough, (B) sore throat, (C) sputum production, (D)malaise, (E) headache, and (F) fever in the HCoV and non-HCoV subsets at
baseline, day 5 and day 10 of the trial (% of patients).
FIGURE 3 | Course of the common cold symptoms (patient diary entries) in the HCoV and non-HCoV subsets during the trial.
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DISCUSSION
In experimental studies, the proanthocyanidin-rich herbal extract
EPs 7630 was shown to display antiviral activity against different
viruses including coronaviruses (Kolodziej, 2011; Michaelis et al.,
2011; Moyo & Van Staden, 2014). In the context of the ongoing
COVID-19 pandemic, it was thus a logical first step to revisit a
previously published clinical trial for further evidence on the
impact of EPs 7630 on HCoV infections.
In the underlying trial, about half of the patients suffering
from the common cold tested positive for at least one of the
investigated viruses, and of these, 23 were shown to be infected
with various HCoVs (Keck et al., 2015). Our analysis of the
clinical manifestations of the common cold found no evidence for
major differences between HCoV positive patients and those
infected with other viruses.
Moreover, HCoV and non-HCoV subsets had similarly
favourable outcomes, with significant improvement of
symptoms already after 5 days of treatment and patients
having largely recovered after 10 days. There was a not
statistically significant trend suggesting superior activity of EPs
7630 in HCoV patients after 5 days of EPs 7630 treatment, which
disappeared at the end of treatment at day 10. These results are in
line with the total symptom scores calculated from the diary
entries. Moreover, the slight but non-significant advantage seen
for HCoV patients in improvement of common cold symptoms is
reflected in the duration of patients’ inability to work, which was
slightly lower in the HCoV subset (0.9 days) compared to the
non-HCoV subset (1.3 days).
It remains unresolved whether patients suffering from
common cold associated with HCoVs as found in the
underlying trial generally recover faster than patients suffering
from common cold caused by other viruses or whether they
responded faster to treatment with EPs 7630. However, existing
studies comparing HCoV infections and viral non-HCoV
infections give no hint towards a generally faster recovery
from HCoV infections (Lau et al., 2006; Gorse et al., 2009;
Gorse et al., 2015). In a prospective cohort-study including
more than 4,000 patients hospitalized for ARTI, Lau et al.
(Lau et al., 2006) compared clinical characteristics in 629
children aged 6 months to 5 years infected with different
viruses. In children, HCoV-HKU1 infections were associated
with a shorter duration of fever and hospitalization and
HCoV-OC43 infections with a shorter duration compared to
most other respiratory viruses. In a prospective cohort study in
2,215 patients with chronic obstructive pulmonary disease
(COPD) presenting for influenza vaccination, no differences
were observed in terms of symptoms, hospitalization rate or
mortality between HCoV and non-HCoV/non-influenza
infections (Gorse et al., 2009). A study of HCoV and other
virus-associated respiratory illnesses reported by Gorse et al.
(Gorse et al., 2015) followed 101 healthy adults aged
18–40 years, a population most similar to the patients included
in our trial, for up to 2 years. The study reported 26 cases of ARTI
with HCoV and 33 cases with other viruses, but no differences
between these groups with regard to the number of symptoms,
the symptoms and signs score, or illness severity measured by
visual analogue scale. Hence, there is no consistent evidence
suggesting a faster recovery from HCoV infections than from
non-HCoV viral ARTI. However, available data are limited and
further investigations are needed to answer whether there may be
differences in disease outcome.
The range of symptoms differed slightly between patients
infected with different viruses. Cough and sore throat were
reported more frequently in the HCoV group at baseline, and
sputum production more frequently in the non-HCoV group.
Remission rates at day 5 were highest for sore throat, malaise, and
headache. In a meta-analysis of placebo-controlled trials, EPs
FIGURE 4 | Treatment outcome (IMOS) and satisfaction with treatment (IMPSS)–% of patients with a favourable response in the HCoV and non-HCoV
subsets (FAS).
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7630 treatment effects on day 7 were estimated to be higher for
cough and headache than for sputum production (Matthys et al.,
2016). Apparently, the somewhat faster recovery of symptom
scores in the HCoV group may reflect differences in the nature of
symptoms caused by HCoV and non-HCoV infections and the
differential impact of EPs 7630 treatment on varying symptoms.
Differences in patient characteristics might have contributed
to the somewhat faster recovery in the HCoV group of the
underlying trial, as patients in this group were slightly
younger. By contrast, the Body Mass Index, the proportion of
current smokers and the rate of infection with multiple viruses
were higher in the HCoV group. However, these differences were
not statistically significant.
The results of our subset analyses are in line with the results
obtained for the whole population of the underlying trial (Keck
et al., 2015; Keck et al., 2018). Therefore, it is not surprising that
patients who tested positive for HCoV NA showed a comparable
course of disease under EPs 7630 treatment as patients infected
with other viruses.
The exact pharmacological mechanisms underlying these
effects are not yet fully understood, but they are most likely
attributable to the antiviral activity against different viruses
including corona viruses shown for EPs 7630 in experimental
studies (Kolodziej, 2011; Michaelis et al., 2011; Moyo & Van
Staden, 2014). Moreover, immunomodulatory activities and
increased ciliary beat frequency (Kolodziej, 2011; Luna et al.,
2011; Theisen & Muller, 2012; Tahan & Yaman, 2013; Helfer
et al., 2014; Witte et al., 2015; Roth et al., 2019; Witte et al., 2020)
could be beneficial in the context of respiratory viral infections.
Patients suffering from COVID-19 are likely to use herbal
medicinal products for early and/or symptomatic management,
particularly for cough, pain, or fever (Silveira et al., 2020). Results
of our comparative analysis show high improvement rates for
cough and sore throat as well as sputum production, headache,
and malaise.
It should be noted, however, that co-medication with
paracetamol was reported by less than 22% of patients, with
no considerable differences between both subsets. This mirrors
results from two meta-analyses of randomized, double-blind,
placebo-controlled trials showing a reduced use of paracetamol
in EPs 7630-treated children suffering from ARTI such as acute
bronchitis and acute tonsillopharyngitis (Seifert et al., 2019;
Seifert et al., 2021). EPs 7630 has no known direct antipyretic
effect. Thus, the authors of the meta-analyses interpreted the
fairly low use of paracetamol as an indicator of a favourable
disease course in which only a minority of EPs 7630-treated
patients developed fever that required antipyretics. Patients may
have benefitted from EPs 7630 due to the pharmacological
activity such as alleviation of cytokine-induced sickness
behaviour and antiviral activity as demonstrated in non-
clinical studies (Nöldner & Schötz, 2007; Theisen & Muller,
2012).
The improvement of symptoms observed in both subsets is
also in line with results reported from randomised, placebo-
controlled clinical trials in patients suffering from the common
cold (Lizogub et al., 2007; Riley et al., 2018; Riley et al., 2019).
In these trials, the symptoms nasal drainage, sore throat, nasal
congestion, sneezing, scratchy throat, hoarseness, cough,
headache, muscle aches, and fever were assessed using an
observer-rated cold intensity score (CIS). The mean CIS as
well as the severity of all individual symptoms decreased at a
noticeably higher rate in the EPs 7630 groups compared to the
placebo group. This also led to a statistically significant
reduction of the primary outcome measure (the sum of
symptom intensity differences of the CIS) in these trials
(Lizogub et al., 2007; Riley et al., 2018; Riley et al., 2019).
Moreover, treatment outcome was significantly better than
placebo according to the IMOS (Lizogub et al., 2007; Riley
et al., 2018; Riley et al., 2019) and patients’ treatment
satisfaction was significantly higher according to the IMPSS
(Riley et al., 2018; Riley et al., 2019), which is also in
accordance with the results of the present subset analysis.
The same applies to the reduced loss of working or study
days reported by EPs 7630-treated patients (Lizogub et al.,
2007; Riley et al., 2018).
A limitation of the present interventional trial is that it was not
intended for demonstrating treatment efficacy but to investigate
EPs 7630 in a well-defined, real-world setting. Due to the lack of a
control group, effects under treatment must be interpreted
cautiously. Nevertheless, the extent of symptom relief was
similar to that in double-blind, randomised, controlled clinical
trials in adults suffering from the common cold (Lizogub et al.,
2007; Riley et al., 2018; Riley et al., 2019), in which EPs 7630 was
shown to be significantly superior to placebo. As a second
limitation, patients who had both a positive test for HCoV
and other viruses were not analysed separately, since patient
numbers were too small. It remains unclear if the presence of
more than one virus is associated with greater disease severity.
Moreover, objective endpoints such as cytokine levels, computed
tomography of lung, or quantitative PCR were not recorded,
which prevents conclusions on the potential modes of action of
EPs 7630.
Our results suggest the hypothesis that EPs 7630 may exhibit
beneficial effects in the treatment of HCoV infections and may
therefore be promising for early therapy or mild courses of SARS-
CoV-2 infections. However, further non-clinical studies and
clinical trials are needed to investigate the therapeutic option
of proanthocyanidin-rich herbal drug preparations like EPs 7630
in HCoV infections in greater detail.
CONCLUSION
Our analyses showed no difference in the disease course
between acute respiratory tract infections in EPs 7630-
treated patients who tested positive for HCoV or other
respiratory viruses. As this trial was conducted before the
pandemic, there is currently no evidence from clinical trials
for the efficacy of EPs 7630 in patients with SARS-CoV-2
infection. Dedicated non-clinical studies and clinical trials are
warranted to further elucidate the potential of EPs 7630 for the
early treatment of HCoV infections. Overall, the presence or
absence of HCoV in common cold does not seem to have an
impact on treatment outcomes.
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